Abstract
Vulvitis circumscripta plasmacellularis (VCP) is a rare but well-described entity. It is notorious for its recalcitrant nature to various modalities of treatment. Intralesional interferon-α showed some promise, with complete resolution, but is coupled with the side-effect of myelosuppression. Topical imiquimod is a novel immune response modifier with the ability to induce the production of interferon-α. In this paper, we report two cases of VCP whose lesions were resistant to antibiotics, topical and oral corticosteroids, but resolved after a treatment trial with imiquimod.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 638-641 |
| Number of pages | 4 |
| Journal | British Journal of Dermatology |
| Volume | 149 |
| Issue number | 3 |
| DOIs | |
| State | Published - Sep 1 2003 |
| Externally published | Yes |
Keywords
- Imiquimod
- Vulvitis circumscripta plasmacellularis
- Zoon's vulvitis
ASJC Scopus subject areas
- Dermatology
Fingerprint Dive into the research topics of 'Resolution of vulvitis circumscripta plasmacellularis with topical imiquimod: Two case reports'. Together they form a unique fingerprint.
Cite this
Ee, H. L., Yosipovitch, G., Chan, R., Ong, B. H., & Ee, M. (2003). Resolution of vulvitis circumscripta plasmacellularis with topical imiquimod: Two case reports. British Journal of Dermatology, 149(3), 638-641. https://doi.org/10.1046/j.1365-2133.2003.05583.x